Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
143
resultados
Última actualización
14/07/2026 [08:30:00]
Resultados 25 a 50 de 143
Resumen de: WO2026142673A1
The invention relates to an active agent increasing the activity of α-carbonic anhydrase (hCA) enzymes, having the potential for use in the treatment of Alzheimer's and certain neurodegenerative disorders.
Resumen de: WO2026142672A1
The invention relates to an active agent increasing the activity of α-carbonic anhydrase (hCA) enzymes, having the potential for use in the treatment of Alzheimer's and certain neurodegenerative disorders.
Resumen de: WO2026139910A1
The invention relates to stable oral formulations of pimavanserin or its pharmaceutically acceptable salts, provided in the form of ready-to-use liquids, powders for reconstitution, orally dispersible tablets, and kits containing pre-measured powder and a liquid vehicle for reconstitution. These formulations are stable for longer periods and are palatable, thereby improving patient compliance and adherence in the treatment of psychosis associated with Parkinson's disease.
Resumen de: WO2026138307A1
New use of 1-amino-3,5-dimethyladamantane hydrochloride in treating or preventing cognitive impairment, reducing microglia in the cortex and hippocampus, reducing neuron loss in the cortex and hippocampus, and ameliorating the mitochondrial dysfunction state. The cognitive impairment includes cognitive impairment in systemic lupus erythematosus, Parkinson's disease, lateral sclerosis, stroke, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, attention deficit hyperactivity disorder, sepsis-related encephalopathy, or mild cognitive disorder. The present application also provides a corresponding drug and a treatment or prevention method.
Resumen de: US20260184772A1
The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or peptide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.
Resumen de: US20260185095A1
Disclosed herein are antisense compounds and methods for decreasing Ataxin 2 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotropic sclerosis (ALS), and parkinsonism.
Resumen de: US20260183333A1
The present invention provides a method of treating frontotemporal dementia, or a childhood genetic neurodegenerative disease such as Ataxia Telangiectasia (A-T), or neurodegenerative diseases such as Parkinson's disease or neuropsychiatric diseases comprising administering to a subject in need thereof an effective amount of chlorite composition, such as sodium chlorite. The present invention thereby provides a method of modulating the immune system in a subject in need thereof. Described herein are methods of administration and treatment.
Resumen de: US20260185159A1
0000 Among the various aspects of the present disclosure is the provision of a method of detecting, preventing, reversing, treating, or delaying the onset of a neurological disease (e.g., adult-onset neurological diseases, Alzheimer's disease, Parkinson's disease, Frontotemporal dementia).
Resumen de: WO2025049336A2
This disclosure relates to methods and compositions for the treatment of Parkinson's disease, a neurodegenerative disorder characterized by a loss of dopaminergic neurons. In particular, this disclosure provides formulations of dopaminergic cells demonstrated to possess a therapeutic impact on both motor and non-motor symptoms of the disease.
Resumen de: EP4768587A1
The present invention provides siRNA, peptide oligonucleotide drugs, and their applications for suppressing the expression of the amyloid precursor protein (APP) gene in human cells. The siRNA exhibits potent activity in inhibiting APP expression. Through appropriate modifications, its ability to silence the target is enhanced while reducing off-target activity. The described siRNA and its conjugates hold promise for clinical application in the prevention and treatment of diseases associated with the APP target, including cerebral amyloid angiopathy (CAA), early-onset familial Alzheimer's disease (EOFAD), or Alzheimer's disease (AD).
Resumen de: EP4768503A1
Provided is an antibody or an antigen-binding fragment thereof that binds to β-Amyloid (Aβ). Further provided are a nucleic acid encoding the antibody or the antigen-binding fragment thereof, a cell comprising the antibody or the antigen-binding fragment thereof or nucleic acid thereof, a pharmaceutical composition, a kit, and the use of the antibody or the antigen-binding fragment thereof in the preparation of a drug used for treating or preventing a disease caused by abnormal accumulation or deposition of Aβ in subjects.
Resumen de: EP4512403A1
Described is a pharmaceutical composition comprising an antagonist/inhibitor of neuropeptide B/W receptor (NPBWR1) for use in in a method of treating, ameliorating or preventing a mood disorder/affective disorder and/or chronic stress and/or anxiety disorders and/or Parkinson's disease. Moreover, described is a pharmaceutical composition comprising an agonist/activator of neuropeptide B/W receptor (NPBWR1) for use in in a method of treating, ameliorating or preventing a bipolar affective disorder (ICD-10 F31) during the manic phase, appetitive disorders, preferably anorexia or bulimia. Further, described is a method for assessing the activity of a candidate molecule suspected of being an antagonist/inhibitor or an agonist/activator of NPBWR1.
Resumen de: EP4768479A1
Compounds represented by the following structure, or tautomers, stereoisomers, hydrates, solvates, pharmaceutically acceptable salts or prodrugs thereof. Said compounds can be used as AT2R agonists.
Resumen de: WO2026136813A1
Disclosed herein is a polynucleotide comprising two or more siRNAs linked together with a single stranded nucleic acid. The two or more siRNAs may bind the same or bind different genes and may comprise a long passenger strand that is annealed to two or more guide strands with gaps of single stranded nucleic acids in between each duplex. Also disclosed herein a method of treating a disease or disorder comprising administering to a subject in need thereof a polynucleotide that targets genes associated with the disorder. The disease may include Alzheimer's disease.
Resumen de: WO2026135697A1
Patients suffering from, or at risk of developing the symptoms of, Alzheimer's disease and related neuroinflammatory-based diseases, are treated by apheresis to selectively withdrawal Galectin-3 from the patient's body. A reduction in the circulating level of gal-3 of the patient of at least 30% of the patient's pre-treatment galectin-3 level should be sufficient to reduce AD symptoms, and/or inhibit AD progression. A greater withdrawal, up to at least 20%, has greater impact. Selective withdrawal of Galectin-3 may be coupled with the administration of MCP to further slow the progress of, and/or reverse, AD symptoms.
Resumen de: WO2026130309A1
A potassium channel gene treatment method for treating Parkinson's disease. A recombinant adeno-associated virus (AAV) nucleotide sequence comprises a nucleotide sequence encoding an inwardly rectifying potassium channel Kir. An AAV vector is used to deliver an inwardly rectifying potassium channel (Kir) gene to the subthalamic nucleus, such that excitability of neurons of the subthalamic nucleus is reduced, so as to alleviate symptoms such as motor deficits caused by excessive excitation of the subthalamic nucleus in patients with Parkinson's disease.
Resumen de: US20260174724A1
0000 A composition for preventing and/or improving brain dysfunction, especially Alzheimer's disease is provided. The composition includes dihydromyricetin or salts thereof, L-theanine, taurine, and cerebroside, which can enhance the intestinal stability and bioavailability of dihydromyricetin and prevent and improve brain dysfunction through multiple mechanisms such as anti-inflammation, inhibition of DNA methylation, elimination of hematoma, and removal of Aβ. In addition, the composition can be used in combination with monoclonal antibody drugs to reduce adverse reactions such as cerebral edema and cerebral hemorrhage that may occur during the treatment of Alzheimer's disease.
Resumen de: AU2024406255A1
Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells. The methods of treatment involve the administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the efficacy of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive function and/or quality of life.
Resumen de: AU2023477048A1
The present invention relates to pharmaceutical compositions and medicaments comprising the compound of formula (I); or a stereoisomer, tautomer, pharmaceutically usable solvate or salt thereof, and dosage regimens for the administration thereof to human patients.
Resumen de: AU2024399699A1
SnRNA systems targeting SOD1 RNA sequences are disclosed herein. Further disclosed are methods of treating Amyotrophic Lateral Sclerosis.
Resumen de: AU2024379023A1
Provided herein are expression cassettes for expressing a transgene in a cell, wherein the transgene encodes a GCase polypeptide. Also provided are methods to treat Gaucher Disease or GBA-PD. Further provided herein are vectors (e.g., rAAV vectors), viral particles, pharmaceutical compositions, and kits for expressing an GCase polypeptide in an individual in need thereof.
Resumen de: US20260176315A1
Use of an interleukin 27 (IL-27) protein in preparation of a product for treating and/or delaying Alzheimer's disease (AD) is provided, belonging to the technical field of biomedicine. The IL-27 protein refers to a recombinant IL-27 protein targeting a therapeutic target IL-27, and is selected from the group consisting of a mouse-derived IL-27 protein and a human-derived IL-27 protein, as well as a mammalian IL-27 protein other than the mouse-derived IL-27 protein and the human-derived IL-27 protein. The recombinant IL-27 protein can effectively alleviate the AD caused by Aβ deposition, and can selectively bind to a target receptor, thereby ensuring an accuracy of test results. The protein receptor is highly expressed in the dentate gyrus region of hippocampus, and guarantees drug targeting to the greatest extent.
Resumen de: US20260174808A1
The present invention relates to a composition for preventing, ameliorating or treating cognitive dysfunction or Alzheimer's disease comprising, as an active ingredient, Lactobacillus fermentum SRK414 strain which has accession number KCTC13687BP. The strain of the present invention is excellent in reducing barrier permeability and reducing amyloid beta and tau proteins and has an excellent effect in improving cognitive function, and accordingly, the strain can be useful for a food and therapeutic agent for same purposes.
Resumen de: US20260174728A1
An orally administered composition positively mitigates the progression of central nervous system diseases such as Alzheimer's, Parkinson's and Multiple Sclerosis. The composition consists of a lipid based blood brain barrier transport medium (Base Transport Sub-Formula) to which other elements (Functional Targeting Compound) may be integrated to mediate specific chemo-neurological dysfunction. It may be administered through the mouth as droplets a spray medium or a chewable tablet.
Nº publicación: US20260176633A1 25/06/2026
Solicitante:
UNIV OF MASSACHUSETTS [US]
University of Massachusetts
Resumen de: US20260176633A1
Aspects of the disclosure relate to compositions and methods useful for treating Huntington's disease. In some embodiments, the disclosure provides interfering nucleic acids (e.g., artificial miRNAs) targeting the huntingtin gene (HTT) and methods of treating Huntington's disease using the same.
BOPI
Sede Electrónica
